Invest now
Concord Drugs share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹71.00(-2.07%)October 8, 2026 15:18:16 PM IST
- NSE
- BSE
- Vol : 3.80 K (NSE + BSE)Last 20 day avg : 5.53 K
Concord Drugs is trading -2.07% lower at Rs 71.00 as compared to its last closing price. Concord Drugs has been trading in the price range of 74.99 & 71.00. Concord Drugs has given -12.10% in this year & -7.36% in the last 5 days. Concord Drugs has TTM P/E ratio 33.76 as compared to the sector P/E of 33.81.The company posted a net profit of 1.11 Crores in its last quarter.Listed peers of Concord Drugs include Sun Pharmaceutical Industries (-1.72%), Divi's Laboratories (-1.99%), Torrent Pharmaceuticals (-0.74%).The Mutual Fund holding in Concord Drugs was at -% in . The MF holding has - from the last quarter. The FII holding in Concord Drugs was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 08 Oct 2026, 10:17 PM IST
- BetaMedium volatility1.08Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.30The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BHigher than historical values1.97The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values32.36Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation-8.87The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Concord Drugs Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,752.50 | -1.72 | 4,20,473.54 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,389.00 | -1.99 | 2,49,248.45 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,675.00 | -0.74 | 1,77,815.61 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,305.00 | -1.84 | 1,05,425.52 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,115.20 | -3.36 | 1,11,241.63 | 21.19 | 4.24 | 0.09 | 14.22 |
Concord Drugs Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-10 | Quarterly Results |
| 2026-05-27 | Audited Results |
| 2026-02-14 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-08 | Quarterly Results |
About the company Concord Drugs
- IndustryBiotechnology & Drugs
- ISININE858L01010
- BSE Code538965
- NSE Code
Concord Drugs Limited is an India-based pharmaceutical company. The Company's principal activity is to manufacture licensed drugs based on the formulations approved. The Company is focused on developing drug delivery systems, including multiple unit pellet system (MUPS), sustained release, and modified release pellets. It operates a Current Good Manufacturing Practice (cGMP) contract manufacturing formulation-fill-finish facility, offering a full spectrum of pharmaceutical development and manufacturing services for drug products. The Company's products include pharmaceutical ready to fill pellets, MUPS; tissue bio adhesive; injectables (small volume parenterals); oral solid dosages (tablets); oral solid dosages (capsules); liquid orals, and dry syrup (powder). It also offers hand sanitizers under the brand name, PROTON SAFE. It manufactures hand sanitizers on third party basis also. The Company's oral liquid dosage forms include solutions, syrups, and suspensions.
Concord Drugs Share Price FAQs
Concord Drugs is trading at 71.00 as on Thu Oct 08 2026 09:48:16. This is -2.07% lower as compared to its previous closing price of 72.50.
The market capitalization of Concord Drugs is 94.77 Cr as on Thu Oct 08 2026 09:48:16.
The 52 wk high for Concord Drugs is 92.52 whereas the 52 wk low is 61.00
Concord Drugs can be analyzed on the following key metrics -
- TTM P/E: 33.76
- Sector P/E: 33.81
- Dividend Yield: 0.00%
- D/E ratio: -
Concord Drugs reported a net profit of 1.06 Cr in 2026.
Quick Links
EQUITY QUICK LINKS
Concord Drugs QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.